Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

Data ReadoutpositiveCAR-TPositive

AI Analysis

Summary

Anixa Biosciences reported positive early clinical data from its CAR-T therapy trial in ovarian cancer, with the first patient achieving stable disease at three months and multiple patients showing extended survival durations. No dose-limiting toxicities were observed to date.

Clinical Trial Data

Phase

Phase_1

Primary Endpoint

Met

Outcome Details

First patient in current dose cohort exhibited stable disease at three months post-treatment with no cancer progression. Multiple patients survived more than one year, one beyond two years. No dose-limiting toxicities observed.

Importance:6/10

Sentiment:

0.75

CAR-Tovarian cancerclinical trialearly-stagesafety profile

Related Companies

$ANIX

Read the original article

Published by PR Newswire Biotech on October 5, 2026 12:15 PM

Read Original